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ABSTRACT
Serious infections caused by Gram-positive pathogens are increasingly difﬁcult to treat because of
pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci
(VRE) and penicillin-resistant Streptococcus pneumoniae. The more recent emergence of vancomycin-
intermediate and -resistant MRSA (VISA and VRSA) has further compromised treatment options.
Reports of resistance to, and clinical failures with newer antimicrobial agents such as linezolid and
quinupristin/dalfopristin are also emerging. Consequently, there is a clinical need for new antimicrobial
agents that have suitable pharmacokinetic properties and safety proﬁles, with activity against these
Gram-positive pathogens.
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INTRODUCTION
Many serious infections are caused by Gram-
positive organisms (Table 1). Their treatment is
highly dependent on the type of infection. Rap-
idly progressive, acute or fulminant infections
such as meningitis, pneumonia, endocarditis and
necrotising fasciitis, require prompt therapy that
is typically empirical. Therapy for serious acute
infections is short term (2–6 weeks) and requires
hospitalisation and intravenous therapy. In the
case of a chronic or indolent infection, such as
osteomyelitis, spondylodiscitis and surgical
implant infection, it is necessary to use patho-
gen-directed therapy after the infection has
undergone microbiological categorisation. Such
chronic infections require long-term suppressive
therapy typically through intravenous induction
in the hospital, followed by maintenance therapy
at home or in the ambulatory setting. Infections
that occur as a result of surgical implants are
particularly important in terms of their clinical
and economic consequences, as they are fre-
quently more difﬁcult to manage because they
require a longer period of antibiotic therapy and
repeated surgical procedures. A recent review by
Darouiche [1] showed that infections associated
with surgical implants in the US had a prevalence
of 2–6% depending on the procedure (Table 2).
This was calculated to have a cost of $15 000–
50 000 per patient.
ANTIMICROBIAL RESISTANCE
AMONG GRAM-POSITIVE
PATHOGENS
Staphylococcus aureus
Methicillin-resistant Staphylococcus aureus (MRSA)
is widespread globally, with USA and Europe
having a similar prevalence (Fig. 1). However, the
distribution of MRSA is highly heterogeneous,
and in Europe, France, Italy and the UK have a
high prevalence (Fig. 2).
MRSA carries a notable clinical risk. Romero-
Vivas et al. [2], comparing patients with bacterae-
mia infected with methicillin-susceptible S. aureus
or MRSA, found that patients infected with
MRSA were more likely to be older, and to have
experienced prolonged hospitalisation, previous
antibiotic therapy, urinary catheter, nasogastric
tube and/or previous surgery. MRSA was
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identiﬁed as a risk factor for outcome (odds ratio,
3), especially in the case of meningitis (odds ratio,
13) or inadequate treatment (odds ratio, 11).
Interestingly, in a comparison of neutropenic
and non-neutropenic patients, S. aureus bacterae-
mia was more serious in non-neutropenic pa-
tients, with attributable mortality of 2.7 and 25.0%
respectively (Table 3) [3]. The reason for this is
unknown, although a low inoculum infection in
neutropenic patients may be involved. As the
application of adequate antibiotic therapy was
also involved, the same study carried out a sub-
analysis of neutropenic (n ¼ 22) and non-neu-
tropenic (n ¼ 22) patients whose in-vitro active
antibiotic therapy started on the same day as the
clinical onset of S. aureus bacteraemia. Overall
mortality and attributable mortality were higher
in the non-neutropenic group (36.5 and 22.7%
respectively); in the neutropenic group, overall
mortality was 13.6% and attributable mortality
was 4.5%.
In recent years, S. aureus with elevated vanco-
mycin MICs have emerged. S. aureus with inter-
mediate susceptibility to vancomycin (MIC 8 mg/
L) were ﬁrst identiﬁed in Japan in 1996 [4], and
subsequent isolates have been identiﬁed in other
parts of the world, including the USA and France
[5,6]. Probable mechanism of resistance is pepti-
doglycan overproduction. Hetero-VISA has also
been reported. Hetero-VISA strains are suscept-
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Fig. 1. Prevalence (%) of methicillin
resistance among Staphylococcus
aureus isolates collected from skin
and soft tissue infections as part of
the SENTRY surveillance pro-
gramme 1997–1999. Adapted from
reference [2].
Table 1. Current and emerging serious infections due to
Gram-positive cocci
Infections Typical organisms
Meningitis Streptococcus pneumoniae
Community-acquired
pneumonia
Streptococcus pneumoniae
Ventilator-associated
pneumonia
Staphylococcus aureus
Bloodstream
infections
Staphylococcus aureus;
Coagulase-negative staphylococci
Endocarditis Viridans group streptococci;
enterococci
Febrile neutropenia Coagulase-negative staphylococci;
viridans group streptococci;
Staphylococcus aureus
Necrotising fasciitis Group A streptococci
Osteomyelitis Staphylococcus aureus
Surgical implants Staphylococcus aureus;
coagulase-negative staphylococci
Line-related
infections
Staphylococcus aureus;
coagulase negative staphylococci
Complicated urinary
tract infections
Enterococci
Table 2. Infections associated with surgical implants: clinical and economic consequences in the USA
Implant
No. of implants
per year
No. of infections
per year
Rate of
infection (%)
Cost ($) per
patient
Heart valve 85 000 3400 4 50 000
Vascular graft 450 000 16 000 4 40 000
Pacemaker–deﬁbrillator 300 000 12 000 4 35 000
Joint prosthesis 600 000 12 000 2 30 000
Fracture-ﬁxation device 2 000 000 100 000 5 15 000
Neurosurgical ventricular shunts 40 000 2400 6 50 000
Mammary plastic 130 000 2600 2 20 000
Urological 15 000 450 3 35 000
Adapted from reference [1].
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ible to vancomycin but contain subpopulations, at
a frequency of 10)6 CFU/mL or higher that grow
at a vancomycin concentration of 4 mg/L and
have MICs of >4 mg/L.
In addition, S. aureus with reduced susceptibil-
ity to vancomycin (SARV) have been described.
Such isolates with a vancomycin MIC of 4 mg/L,
are associated with the clinical failure of vanco-
mycin in the treatment of MRSA infection. Con-
sequently, the clinical management of serious
infections such as infective endocarditis is
increasingly difﬁcult. In the case of four patients
with SARV infective endocarditis, two with left
sided endocarditis died, one with right sided
endocarditis was cured with vancomycin and
rifampicin, and one with left sided endocarditis
was cured with linezolid [7].
The VISA and SARV isolates collected to date
were multi-drug resistant, but have remained
susceptible to rifampicin, co-trimoxazole and
tetracycline.
Following the development of VISA and SARV,
vancomycin-resistant MRSA (VRSA) has now
emerged. Three isolates have been identiﬁed to
date in the USA, from Michigan, Pennsylvania
and more recently, New York [8–10]. The Mich-
igan isolate had a vancomycin MIC of 1024 mg/L,
was also resistant to teicoplanin, and was positive
for vanA. The gene appeared to have been
acquired from an enterococcus (see below) [11].
The vancomycin MIC of the Pennsylvania VRSA
was 32 mg/L, and although it was positive for the
vanA gene, its phenotype was vanB (vancomycin
resistant but susceptible to teicoplanin) [12]. It is
important to stress that the VRSA isolate from
Pennsylvania was acquired in the community
setting and the patient reported no recent use or
exposure to vancomycin [13].
In addition to the evolution of resistance to
established agents, resistance has also been repor-
ted to antimicrobial agents that have come to the
market in recent years. A study from the SENTRY
surveillance programme in 2001 reported that
1.2% (35/3052) of S. aureus isolates collected from
European hospitals were non-susceptible to qui-
nupristin/dalfopristin (MIC ‡2 mg/L) [14]. These
Table 3. Case–control studybetween
neutropenic, haematological patients
and non-neutropenic non-haemato-
logical patients with Staphylococcus
aureus bacteraemia
Neutropenic
patients
Non-neutropenic
patients p-Value
No. of patients 36 36
Mucositis 14 (38.8%) 0 <0.001
Mean (range) illness score 1.28 (0–9) 2.8 (1–12) <0.001
Severe sepsis or septic shock 1 10 (27.7%) 0.002
Mean (range) days of
hospitalisationa
27.2 (4–59) 44.5 (6–103) 0.004
Days of adequate treatment 1.18 (0–4) 1.96 (0–7) 0.02
Duration of fever 4.1 (1–14) 6.3 (0–31) 0.052
Duration of antibiotic therapy 9.3 (3–22) 19.6 (3–63) 0.009
Duration of bacteraemia 1.33 (1–6) 1.95 (1–7) 0.03
Relapse rate 4 (11.1%) 2 (5.5%)
Metastatic infections 0 5 (13.8%) 0.02
Overall mortality 4 (11.1%) 13 (36.1%) 0.01
Attributable mortality 1 (2.7) 9 (25%) 0.006
Reproduced from reference [3].
aExcluding patients who died during hospitalisation.
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Fig. 2. Prevalence (%) of methicillin
resistance among Staphylococcus
aureus isolates in Europe in 2002.
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isolates were collected from four hospitals in
France and one in Spain. All 35 isolates were also
glycopeptide-intermediate. In addition, clinical
failures have been reported for the oxazolidinone
linezolid, involving both susceptible (linezolid
MIC 4 mg/L) and resistant (linezolid MIC
‡8 mg/L) isolates [15–17]. In the ﬁrst report of
linezolid-resistant MRSA in the clinic, three iso-
lates (linezolid MIC >32 mg/L) were collected
from a patient in the US treated for dialysis-
associated peritonitis; two isolates were indistin-
guishable from each other by PFGE and the third
differed by a single band [16]. The second, in
2002, involved a patient in the UK who under-
went thoracotomy and drainage of empyema [17];
separate populations of MRSA containing some
colonies that were linezolid-susceptible (MIC 1–
2 mg/L) and others that were linezolid-resistant
(MIC 8–32 mg/L) were isolated. In this case,
linezolid resistance emerged from a susceptible
strain during treatment.
Coagulase-negative staphylococci
As with S. aureus, glycopeptide resistance was
reported among the coagulase-negative staphylo-
cocci (CNS). However, for CNS, there is no clear
correlation between oxacillin resistance and the
presence of the mecA gene as there is for S. aureus.
For example, in Staphylococcus haemolyticus there
is a clear relationship between mecA and resist-
ance, whereas for Staphylococcus cohnii the MIC for
oxacillin is ‡0.5 mg/L for isolates that carry the
mecA gene and those that do not (Table 4).
Johnson et al. [18] reported a prevalence of
1.2% vancomycin resistance among CNS in the
UK in 2002. The prevalence of resistance to
teicoplanin was much higher at 13.7%; this
was most probably because of the presence of
S. haemolyticus among the CNS (Table 5). Staphy-
lococcus haemolyticus is particularly important to
consider when treating bacteraemia in febrile
neutropenic patients.
Enterococci
Enterococci are part of the normal intestinal ﬂora.
However, the presence of virulence genes has
meant they have become an important considera-
tion in the treatment of serious Gram-positive
infections [19]. Of great concern is the acquired
resistance of enterococci such as Enterococcus
faecium and Enterococcus faecalis. In these species,
several genes mediate resistance, the most com-
mon of which are vanA and vanB. Isolates that
carry the vanA gene typically demonstrate high
vancomycin and teicoplanin MICs, whereas those
isolates that carry the vanB gene are resistant to
vancomycin (but with a lower MIC than vanA
isolates) and susceptible to teicoplanin. The pre-
valence of vancomycin-resistant enterococci
Table 4. Coagulase-negative staphylococci: correlation
between oxacillin MIC and mecA gene
Species
Presence (+) or
absence ()) of
mecA
Oxacillin
MIC (mg/L)
S. epidermidis, S. hominis,
S. haemolyticus
+ ‡0.5
) £0.25
S. cohnii, S. saprophyticus,
S. warneri
+ ‡0.5
) ‡0.5 (91.3%)
S. lugdunensis, S. xylosus not reported always ‡0.5
S. capitis, S. schleiferi,
S. simulans
not reported always £0.25
Adapted from reference [25].
MIC, minimum inhibitory concentration.
Table 5. Glycopeptide and strep-
togramin resistance in methicillin-
resistant Staphylococcus aureus,
methicillin-resistant Staphylococcus
epidermidis and Staphylococcus haemo-
lyticusa
Staphylococcus
spp.
No. of
strains
Resistance (%)
Vancomycin Teicoplanin Quinupristin/dalfopristina
MRSA 1749 0 0.1 1
MRSE 914 0 4 2
MRSH 257 0 48 2
Adapted from reference [26].
MRSA, methicillin-resistant Staphylococcus aureus; MRSE, methicillin-resistant
Staphylococcus epidermidis; MRSH, methicillin-resistant Staphylococcus haemolyti-
cus.
aIncluding intermediate resistance.
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(VRE) is highly variable across Europe and seems
to be high in Italy (because of local epidemics)
and the UK (Fig. 3). VRE is a particular problem
in large hospitals and the risk factors commonly
associated are severe underlying disease, pro-
longed hospital stay and previous antibiotic
therapy. Treatment options are limited as VRE
are typically multi-drug resistant, with vancomy-
cin-resistant E. faecium known to be very often
resistant to high concentrations of aminoglyco-
sides, to ampicillin and to the ﬂuoroquinolones in
addition to the glycopeptides.
Recently, the transfer of the vancomycin resist-
ance genes from the enterococci into other species
has been realised with the emergence of vanco-
mycin-resistant MRSA.
The treatment of VRE remains a challenge
despite the advent of new agents, such as linezo-
lid, with activity against VRE. A European study
conducted in 2001 collected 108 faecal and 26
clinical isolates with the VanA phenotype, of
which 87 and 81% were gentamicin resistant,
respectively, 4 and 4% were quinupristin/dal-
fopristin resistant, respectively, and 2 and 0%
were linezolid resistant, respectively [20]. It has
not taken long for clinical reports of enterococcal
resistance to linezolid to emerge. Linezolid was
licensed in the UK in early 2001; in 2002 Auckland
and colleagues reported the ﬁrst cases of resistant
enterococci in that country [21]. The linezolid MIC
of the resistant isolates was 64 mg/L; two of the
isolates were E. faecium and one was E. faecalis.
Resistance developed in previously susceptible
strains, most probably through point mutation in
the 23S rRNA.
With the advent of these resistant isolates, it is
important to stress the role that prevention
strategies must play in the battle against antimi-
crobial resistance. Using a mathematical model,
Perencevich et al. [22]. predicted that active sur-
veillance and contact precautions for all colonised
patients would provide signiﬁcantly better con-
trol than standard precautions and/or isolation of
the small minority of colonised patients recog-
nised by routine clinical cultures. Presumptive
isolation at the time of ICU admission, pending
surveillance culture results, would add signiﬁ-
cantly to this control. In addition, efﬁcacy may be
increased by the use of this strategy throughout
the entire hospital. This would also be the case for
MRSA.
Streptococcus pneumoniae
Penicillin non-susceptible Streptococcus pneumoni-
ae occurs through alterations in penicillin-binding
proteins, which results in a lower afﬁnity for
penicillin. In-vitro resistance is categorised as
either intermediate (MIC 0.12–1 mg/L) or resist-
ant (MIC ‡2 mg/L) [23]. However, treatment
options are dependent on the infection to be
treated, as in the clinical setting an intermediate
strain may behave as clinically susceptible when
it causes pneumonia but not when it causes
meningitis. Therefore, in the case of infections
caused by intermediate S. pneumoniae isolates,
agents such as ceftriaxone or cefotaxime can be
used as treatment as long as the patient does not
have meningitis. Treatment options are further
complicated as penicillin non-susceptible S. pneu-
moniae are typically resistant to multiple drugs
such as erythromycin, tetracycline and co-trim-
oxazole. Penicillin non-susceptible S. pneumoniae
are a problem all over the world, both in the
community and hospital setting. In 2002, the
EARSS project reported ﬁve countries with a
prevalence of penicillin non-susceptible S. pneu-
moniae of greater than or equal to 30% (Fig. 4)
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Fig. 3. Rate of VanA and VanB
types among 1314 clinical entero-
coccal isolates. Reproduced from
reference [20] with permission.
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[http://www.earss.rivm.nl]. Overall, in 2002 the
EARSS project reported 11% of S. pneumoniae as
non-susceptible to penicillin and 17% as non-
susceptible to erythromycin [http://www.earss.
rivm.nl].
Viridans group streptococci
Viridans group streptococci are particularly
important pathogens causing bacteraemia in feb-
rile neutropenic patients, a particularly severe
clinical syndrome. Cordonnier et al. [24] found
that streptococcal infection was associated with
diarrhoea, use of non-absorbable antifungal
agents, high-dose cytarabine and gut decontam-
ination with colistin. The relative risks for strep-
tococcal infections were 2.9, 13.2 and 20.7 in
the presence of one, two and three or more
parameters, respectively. Complications that com-
monly arise in neutropenic patients with viridans
streptococcal bacteraemia include pneumonia (3–
31%), acute respiratory distress syndrome (3–
33%), hypotension (5–37%), shock (7–18%) and
endocarditis (7–8%). Mortality is reported to
occur in 6–30% of the patients.
CONCLUSIONS
Staphylococci, enterococci and streptococci are
responsible for a variety of serious infections, with
variable resistance levels to established agents
according to pathogen, country and hospital set-
ting. As a result of the high prevalence of resist-
ance to some agents and the emergence of
resistance to newer agents, treatment options are
limited. As an additional complication, there is
also the issue of safety with some of the newer
agents. Therefore, there is an unmet clinical need
for new agents with activity against Gram-positive
pathogens, including those resistant to current
drugs, which have convenient pharmacokinetics
and a good safety proﬁle. However, it is important
to stress that the solution to the global problem of
antimicrobial resistance lies not just in developing
new agents. Other factors also have a role to play,
including the use of vaccination to prevent bac-
terial infections, the prudent use of current agents,
the appropriate use of antimicrobial combinations
and the control and prevention of the dissemin-
ation of antibiotic-resistant organisms. The dis-
covery and development of new agents should ﬁt
within this framework.
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